Receptor-positive breast cancer means the cancer cells have surface proteins — receptors — that bind to hormones such as estrogen or progesterone and use them to fuel growth. This status is determined by pathology testing of a biopsy sample and is important because receptor-positive cancers can often be treated with hormone-blocking therapies.
What is receptor positive?
When cancer cells are described as receptor positive, it means they carry protein molecules on their surface that act as docking sites for hormones. Estrogen receptor positive (ER+) and progesterone receptor positive (PR+) are the most common designations. When these hormones bind to the receptors, they signal the cell to grow and divide — which means that reducing hormone levels, or blocking the receptors, can slow or stop the cancer.
A pathologist determines receptor status by analyzing a sample of the tumor, typically obtained through a biopsy. The results are reported as a percentage of cells that test positive and the intensity of the staining. Even a small percentage of receptor-positive cells can influence treatment recommendations, since hormone-blocking therapy may reach those cells effectively.
Receptor-positive breast cancer is the most common subtype and, in many ways, one of the most treatable. Medications like tamoxifen and aromatase inhibitors are designed specifically to interfere with the hormone signaling that feeds these cancers. Many people take these medications for five to ten years after initial treatment to significantly reduce the risk of recurrence. Your pathology report will clearly state your receptor status, and it is worth discussing what the numbers mean for your specific situation with your oncologist.
Why it matters
Receptor status is one of the most important factors shaping a breast cancer treatment plan. Receptor-positive cancers have access to a wide range of hormone-targeted therapies that are generally well tolerated compared to chemotherapy, and decades of research support their effectiveness in reducing recurrence.
Knowing your receptor status also helps clarify prognosis. In general, hormone receptor-positive breast cancers tend to grow more slowly than receptor-negative types, which can allow for more treatment options and careful planning. Being informed about your status empowers you to ask meaningful questions — such as which hormone therapy is recommended, how long treatment will last, and what to expect during that time.
Related terms
Related articles
Medical disclaimer